Loading
Senticell, a University of Pennsylvania spinout, is developing a blood test that reads genetic material carried on red blood cells, a source most liquid biopsies ignore, to find cancer mutations from a single blood draw.
Senticell is a molecular diagnostics company that grew out of research at the University of Pennsylvania and licenses the technology from it. Its platform analyses nucleic acids bound to red blood cells together with cell-free DNA, and the company says it can detect disease-specific RNA, cfDNA and protein biomarkers from one blood sample. It is led by physician-scientist Nilam Mangalmurti. Trade reports in September 2026 described an oversubscribed seed round approaching USD 7 million and two prospective studies at Penn Medicine enrolling about 300 patients with lung, pancreatic, head and neck and cervical cancers.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/